DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 18-031/S-030
NDA 19-059/S-016

Wyeth-Ayerst
Attention: Ms. Mary Alice Dankulich
170 Radnor Chester Road
St. Davids, PA 19087

Dear Ms. Dankulich:

Please refer to your supplemental new drug applications dated August 24, 2000, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Inderide (Propranolol HCL/Hydrochlorothiazide) 40/25 and 80/25 mg Tablets (NDA 18-031), and Inderide (Propranolol HCL/Hydrochlorothiazide) 80/50, 120/50 and 160/50 mg LA Capsules (NDA 19-059).

We acknowledge receipt of your submissions dated June 21, 2001 that constituted a complete response to our January 12, 2001 action letter.

These supplemental new drug applications provide for final printed labeling with the following revisions:

NDA 18-031

Geriatric Use
Clinical studies of Inderide did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

NDA 19-059

1. Geriatric Use
   Clinical studies of Inderide LA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

   In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

2. Under WARNINGS/Propranolol Hydrochloride (Inderal), the following sentence has been added to the end of that section to be consistent with labeling for NDA 18-031:

   Acute increases in blood pressure have occurred after insulin-induced hypoglycemia in patients on propranolol.

3. Under the PRECAUTIONS/Nursing Mothers/Hydrochlorothiazide section, the following sentence has been added to be consistent with labeling for NDA 18-031:

   Thiazides appear in breast milk. If use of the drug is deemed essential, the patient should stop nursing.

NDAs 18-031 and 19-059

In addition, the statement in the header, “Caution: Federal law prohibits dispensing without prescription.” has been replaced with, “Rx only.”

We have completed the review of these supplemental applications, as amended, and have concluded that adequate information has been presented to demonstrate that the drug products are safe and effective for use as recommended in the final printed labeling included in your June 21, 2001 submissions. Accordingly, these supplemental applications are approved effective on the date of this letter.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions please call:

Ms. Zelda McDonald
Regulatory Health Project Manager
(301) 594-5333

Sincerely,

{See appended electronic signature page}

Raymond J. Lipicky, M.D.
Director
Division of Cardio-Renal Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Raymond Lipicky

11/1/01 01:49:54 PM